Go Pro
NASDAQ:DRUG

Bright Minds Biosciences Q2 2026 Earnings Report

Bright Minds Biosciences logo
$57.92 -2.75 (-4.53%)
Closing price 04:00 PM Eastern
Extended Trading
$58.00 +0.08 (+0.14%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bright Minds Biosciences EPS Results

Actual EPS
-$0.80
Consensus EPS
-$0.86
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Bright Minds Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bright Minds Biosciences Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 19, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Bright Minds Biosciences Earnings Headlines

Bright Minds Biosciences to Present at Upcoming Conferences
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
See More Bright Minds Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bright Minds Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bright Minds Biosciences and other key companies, straight to your email.

About Bright Minds Biosciences

Bright Minds Biosciences (NASDAQ:DRUG) is a biotechnology company focused on developing next-generation therapies for neuropsychiatric and neurological disorders. The company’s research centers on selective serotonin receptor agonists designed to address conditions such as treatment-resistant depression, substance use disorders and other disorders involving disrupted brain signaling.

Bright Minds’ lead program, BMB-101, is an orally administered, selective 5-HT2C receptor agonist being developed as a potential treatment for conditions including substance use disorder and related neuropsychiatric indications. The company’s drug-development approach is intended to preserve therapeutic effects while reducing some of the adverse effects and limitations associated with less selective psychedelic or serotonergic compounds.

Bright Minds Biosciences is based in Vancouver, British Columbia, and conducts biotechnology research and clinical development activities through operations in North America. Its shares trade on the Nasdaq Capital Market under the symbol “DRUG” and on the Canadian Securities Exchange under the same symbol.

View Bright Minds Biosciences Profile